Ruxolitinib 1.5% cream,
does it really help with Facial repigmentation in nonsegmental vitiligo?
research showsRuxolitinib 1.5% cream repigments facial nonsegmental vitiligo but is rated C. TRuE-V1 randomized 330 and analyzed all 330 for efficacy; TRuE-V2 randomized 344 and analyzed 331 for efficacy. The week-24 primary F-VASI75 endpoint succeeded in both trials, at 29.8% versus 7.4% and 30.9% versus 11.4%, respectively, P<.001. Both trials and the preceding phase 2 study belonged to the same development program fully funded and led by Incyte, with no independent confirmatory randomized trial. Rule ②-b caps entirely manufacturer-only positive evidence at C, giving 58 points.
ads claimPromotion may expand a week-24 response into complete whole-body or permanent repigmentation for everyone. The primary outcome was 75% improvement on a facial score, and about 70% of treated participants did not meet it by week 24.
Useful facts when choosing a product
- Evidence applies to patients aged at least 12 years with nonsegmental vitiligo under specified facial and body-area criteria.
- Trials applied cream twice daily to facial and body lesions for 24 weeks and continued through week 52.
- Application-site acne and pruritus and nasopharyngitis were commonly reported.
- This prescription JAK inhibitor should remain within labeled body-area and dose limits; infection, immunosuppression, or another JAK inhibitor requires prescriber review.
What the research actually shows
The phase 3 trials assigned participants aged at least 12 years with nonsegmental vitiligo affecting no more than 10% of body-surface area in a 2:1 ratio to ruxolitinib or vehicle. Actual primary efficacy populations were 330 in TRuE-V1 and 331 in TRuE-V2, and both F-VASI75 endpoints succeeded. A preceding 157-person phase 2 trial also showed dose response and repigmentation but was funded by the same manufacturer.
Why this is classified as C (58)
Both primary F-VASI75 endpoints succeeded in actual efficacy populations of 330 and 331, but the phase 2 and both phase 3 trials were funded by the same manufacturer and lack independent confirmation. Rule ②-b caps the grade at C with 58 points.
Counterpoint. Response varies by site and duration, and the face generally responds better than hands and feet, so complete whole-body restoration should not be expected.
Rejudgment record. Cross-check applied — Distinguished 330 randomized and 330 analyzed in TRuE-V1 from 344 randomized and 331 analyzed in TRuE-V2, then applied the rule ②-b ceiling despite success of both primary endpoints because all evidence came from one manufacturer
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| At least 75% facial repigmentation by week 24 | C | Both phase 3 primary endpoints succeeded, but all evidence came from the same manufacturer. |
| Continued facial repigmentation through week 52 | C | Responses increased during extension, but all participants received active drug after week 24, leaving no long-term control. |
| Patient-perceived improvement in vitiligo noticeability | C | The key secondary patient-reported outcome was positive but lacks independent replication. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Rosmarin D et al. 2022, TRuE-V1 and TRuE-V2 | Two phase 3 multicenter double-blind vehicle-controlled randomized trials | 331 | Fully funded and led by Incyte | Primary: at least 75% improvement in facial Vitiligo Area Scoring Index at week 24 | Both primary endpoints succeeded: V1 29.8% versus 7.4%, RR 4.0; V2 30.9% versus 11.4%, RR 2.7; both P<.001. | Key twin phase 3 trials from a single manufacturer program |
| Rosmarin D et al. 2020 | Phase 2 randomized double-blind vehicle- and dose-controlled trial | 157 | Fully funded and led by Incyte | Primary: F-VASI50 response at week 24 | Twice-daily ruxolitinib 1.5% produced significantly more facial repigmentation responses than vehicle. | Preceding dose-response evidence from the same manufacturer |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Ruxolitinib 1.5% cream x facial repigmentation in nonsegmental vitiligo — Evidence Grade C·58. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/topical-ruxolitinib-cream-nonsegmental-vitiligo-facial-repigmentation/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.